Deleted Tweets From Scott Gottlieb, R-D.C.

RT @SecAzar: It was great to address #NAMD2018 today, where we announced CMS will be providing historic new flexibility around the IMD exclusion for treating patients with serious mental illness. https://

RT @US_FDA: Excited to join @NCIDirector Dr. Ned Sharpless for the #chasingcancer Summit. https://t.co/ICdv0SALoi

My #FDA colleagues and I are grateful for @NASEM_Health’s contribution to efforts to establish evidence-based guidelines that can inform proper prescribing and rationalize how opioid drugs are being used: https://t.co/XWXAr4iKLV

RT @CancerResrch: Abram calls @FDAOncology a catalyst for harnessing talent from the medical product centers; potential to think about how this can be applied more broadly so patients with other conditions and

RT @FDASpox: OPIOID FLAG: @SGottliebFDA’s remarks at @NASEM_Health’s kick-off meeting for its work related to #FDA’s contract to help advance the development of evidence-based, indication-specific guideli

RT @CancerResrch: For more information on our joint project on clinical trial eligibility criteria with @ASCO: https://t.co/szvwr49ucq #FriendsAM18 #ProgressForPatients https://t.co/cbsGG6ryPC

RT @Ramsey_Baghdadi: Abram said they have money in the FY19 budget for this and focusing on labels for cancer drugs first. https://t.co/q6621SIwgO

FDA issues warning letter to company illegally marketing an unapproved cellular product manufactured in a facility with significant manufacturing violations, putting patients at risk https://t.co/vNeewJIoph

The potential benefits of regenerative medicine have spurred major progress in stem-cell biology over the past several decades. But we continue to see bad actors exploit the promise of this field to mislead vulnerable patients about the safety and efficacy of these treatments

We support sound, scientific research and regulation of cell-based regenerative medicine, which is seen in our comprehensive policy framework to promote the efficient approval of regenerative medicine products https://t.co/hzmeMZN5NT

RT @FDASpox: FDA is taking steps to allow greater flexibility for clinical investigators regarding informed consent in minimal risk situations. Read more about this proposed rule and its authorities, if f

RT @d2merino: Such an honor to have Deputy Commissioner for Policy at @US_FDA, discussing the importance of the Oncology Center of Excellence @FDAOncology in improving the lives of patients with cancer #Fr

We’re deeply concerned about the epidemic of youth use of e-cigs. Voluntary action is no substitute for regulatory steps #FDA will soon take. But we want to recognize actions by JUUL today and urge all manufacturers to immediately implement steps to start reversing these trends. https://t.co/blaoZDHRRj

THREAD: #FDA has received feedback about conducting important minimal risk clinical investigations where obtaining informed consent was not practicable, and today we’re issuing a proposed rule which would allow greater flexibility. https://t.co/o8q8pEw7Pp

The proposed changes would facilitate the conduct of certain minimal risk clinical investigations that may be important to addressing significant public health needs without compromising the rights, safety, or welfare of human subjects.

RT @realDonaldTrump: It was my great honor to host a celebration of Diwali, the Hindu Festival of Lights, in the Roosevelt Room at the @WhiteHouse this afternoon. Very, very special people! https://t.co/kQk7IvpSF

RT @FDAOncology: Talk with #FDAOncology experts. Join us in person or online at our 2nd annual educational workshop for new cancer patient advocates, Partners in Progress #OCEPIP18 https://t.co/srXaLZluS0 htt

RT @SecAzar: Today at lunch, @HHSGov leadership and staff enjoyed a Thanksgiving meal here at the Humphrey Building. I’m grateful to work with an incredible group of people so committed to improving the h

The proposed rule, if finalized, would permit an exception from existing informed consent requirements when clinical tests pose no more than minimal risk to human subjects.

RT @NCIDirector: Glad to join @SGottliebFDA & @lauriemcginley2 this morning for an important discussion on #cancerresearch and public health. The NCI and FDA are working together closely to benefit patie

RT @SecAzar: It was great to address #NAMD2018 today, where we announced CMS will be providing historic new flexibility around the IMD exclusion for treating patients with serious mental illness. https://

RT @US_FDA: Excited to join @NCIDirector Dr. Ned Sharpless for the #chasingcancer Summit. https://t.co/ICdv0SALoi

My #FDA colleagues and I are grateful for @NASEM_Health’s contribution to efforts to establish evidence-based guidelines that can inform proper prescribing and rationalize how opioid drugs are being used: https://t.co/XWXAr4iKLV

RT @CancerResrch: Abram calls @FDAOncology a catalyst for harnessing talent from the medical product centers; potential to think about how this can be applied more broadly so patients with other conditions and

RT @FDASpox: OPIOID FLAG: @SGottliebFDA’s remarks at @NASEM_Health’s kick-off meeting for its work related to #FDA’s contract to help advance the development of evidence-based, indication-specific guideli

RT @CancerResrch: For more information on our joint project on clinical trial eligibility criteria with @ASCO: https://t.co/szvwr49ucq #FriendsAM18 #ProgressForPatients https://t.co/cbsGG6ryPC

RT @Ramsey_Baghdadi: Abram said they have money in the FY19 budget for this and focusing on labels for cancer drugs first. https://t.co/q6621SIwgO

FDA issues warning letter to company illegally marketing an unapproved cellular product manufactured in a facility with significant manufacturing violations, putting patients at risk https://t.co/vNeewJIoph

The potential benefits of regenerative medicine have spurred major progress in stem-cell biology over the past several decades. But we continue to see bad actors exploit the promise of this field to mislead vulnerable patients about the safety and efficacy of these treatments

We support sound, scientific research and regulation of cell-based regenerative medicine, which is seen in our comprehensive policy framework to promote the efficient approval of regenerative medicine products https://t.co/hzmeMZN5NT

RT @FDASpox: FDA is taking steps to allow greater flexibility for clinical investigators regarding informed consent in minimal risk situations. Read more about this proposed rule and its authorities, if f

RT @d2merino: Such an honor to have Deputy Commissioner for Policy at @US_FDA, discussing the importance of the Oncology Center of Excellence @FDAOncology in improving the lives of patients with cancer #Fr

We’re deeply concerned about the epidemic of youth use of e-cigs. Voluntary action is no substitute for regulatory steps #FDA will soon take. But we want to recognize actions by JUUL today and urge all manufacturers to immediately implement steps to start reversing these trends. https://t.co/blaoZDHRRj

THREAD: #FDA has received feedback about conducting important minimal risk clinical investigations where obtaining informed consent was not practicable, and today we’re issuing a proposed rule which would allow greater flexibility. https://t.co/o8q8pEw7Pp

The proposed changes would facilitate the conduct of certain minimal risk clinical investigations that may be important to addressing significant public health needs without compromising the rights, safety, or welfare of human subjects.

RT @realDonaldTrump: It was my great honor to host a celebration of Diwali, the Hindu Festival of Lights, in the Roosevelt Room at the @WhiteHouse this afternoon. Very, very special people! https://t.co/kQk7IvpSF

RT @FDAOncology: Talk with #FDAOncology experts. Join us in person or online at our 2nd annual educational workshop for new cancer patient advocates, Partners in Progress #OCEPIP18 https://t.co/srXaLZluS0 htt

RT @SecAzar: Today at lunch, @HHSGov leadership and staff enjoyed a Thanksgiving meal here at the Humphrey Building. I’m grateful to work with an incredible group of people so committed to improving the h

The proposed rule, if finalized, would permit an exception from existing informed consent requirements when clinical tests pose no more than minimal risk to human subjects.

RT @NCIDirector: Glad to join @SGottliebFDA & @lauriemcginley2 this morning for an important discussion on #cancerresearch and public health. The NCI and FDA are working together closely to benefit patie